Chemomab Therapeutics Ltd ADR CMMB

$1.19 +0.05 (4.39%)

Valuation

Market cap
8,622,000
Revenue TTM
$0
Net income TTM
$-9,000,000
P/E (trailing)
0.00
P/E (forward)
—
Profit margin
0.00%
Debt to equity
0.00

Trading

Volume
70,800
Avg volume
94,316
Day's range
$1.13 – $1.33
Shares out
7,246,000
Stochastic %K
15%
Beta
0.80
Analysts
Strong Buy
Price target
$5.00

Price

Company profile

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of therapeutics for the treatment of fibrotic and inflammatory diseases. Its lead product candidate is nebokitug, a humanized monoclonal antibody that attenuates the basic function of CCL24 as a regulator of major inflammatory and fibrotic pathways, which has completed phase 2 clinical trial for treating prima...

Show more

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of therapeutics for the treatment of fibrotic and inflammatory diseases. Its lead product candidate is nebokitug, a humanized monoclonal antibody that attenuates the basic function of CCL24 as a regulator of major inflammatory and fibrotic pathways, which has completed phase 2 clinical trial for treating primary sclerosing cholangitis, as well as in phase 2 clinical trial to treat systemic sclerosis. The company was founded in 2011 and is based in Tel Aviv-Yafo, Israel.

Industry
Biotechnology
Sector
Healthcare
Phone
972 77 331 0156
Website
https://www.chemomab.com
Address
Building C, 10th Floor 10 Habarzel Street, Tel Aviv-Yafo, Israel

Latest news

No headlines yet.